parameters such as ICD-10 codes, lab values, or medication lists.

Step 2: Identify Suitable EHR Data Sources

• Hospital-based EHR systems (e.g., Epic, Cerner)
• Integrated Delivery Networks (IDNs)
• National health data networks
• Claims-EHR linked databases
• Research platforms like PCORnet, OHDSI, or TriNetX

Make sure the data source covers your population and has sufficient follow-up duration.

Step 3: Ensure Data Access and Legal Compliance

Obtain data use agreements (DUAs), IRB approvals, and confirm HIPAA compliance. If using de-identified or limited datasets, ensure they follow the Safe Harbor method or expert determination rules.

For international datasets, verify compliance with GDPR or local data protection regulations.

EHR Data Extraction and Curation Techniques:

EHR data is often messy and incomplete. It is essential to curate data before using it in RWE studies.

1. Extract: Pull structured (e.g., demographics, labs) and unstructured (e.g., clinical notes) data.
2. Transform: Map diagnosis/procedure codes (ICD-10, SNOMED, LOINC) into a common data model.
3. Clean: Address missing values, outliers, or implausible records.
4. Link: Combine data from multiple sources (EHR + claims or registries).

Platforms like OMOP CDM standardize these tasks for global pharma research.

Handling Structured and Unstructured Data in EHRs:

Structured EHR data includes diagnosis codes, lab values, vital signs, etc. Unstructured data includes physician notes, radiology reports, and discharge summaries.

Use Natural Language Processing (NLP) tools to extract key variables from unstructured data. Combine both data types for improved RWE accuracy and completeness.

Ensure that pharmaceutical SOP guidelines are followed when working with NLP algorithms or machine-learning techniques for data extraction.

Ethical and Regulatory Considerations in EHR-Based Research:

EHR data often includes sensitive personal health information (PHI). To remain compliant:

• Get IRB or ethics committee approval, even for de-identified data
• Implement data encryption and access controls
• Use secure servers and data audit trails
• Train staff on GCP and data privacy standards

According to CDSCO and GMP guidelines, all data handling must be traceable and auditable.

Study Designs That Work Well with EHR Data:

• Retrospective Cohort Studies: Identify exposure and track outcomes over time.
• Case-Control Studies: Match cases and controls using demographic or clinical variables.
• Nested Case-Control: Use cohort data for efficient rare outcome studies.
• Cross-sectional Analysis: Evaluate prevalence or current treatment patterns.

These designs can be enhanced with real-time patient registries or longitudinal data sources available in EHRs.

Benefits and Limitations of EHR Data in Pharma Studies:

Advantages:

• Rich longitudinal clinical data
• Scalable access to large patient populations
• Reduced need for patient re-contact
• Supports predictive analytics and machine learning

Limitations:

• Data fragmentation across healthcare systems
• Variable data quality and missingness
• Inconsistent coding and documentation practices
• Complex de-identification and linkage processes

Work with data scientists and biostatisticians to mitigate these challenges. Standardize procedures with validation protocols for EHR-derived datasets.

Ensuring Data Quality and Validation:

Before using EHR data for submission or regulatory insights, ensure that quality metrics are in place:

• Completeness and accuracy checks
• Validation against external registries or benchmarks
• Consistency across data elements
• Timeliness and relevance of captured data

Use logic rules and medical coding algorithms to verify extracted datasets.

Checklist for Pharma Teams Using EHRs in RWE Studies:

• ☑ Define study objectives and eligibility using EHR variables
• ☑ Secure ethical approvals and DUAs
• ☑ Extract and clean structured/unstructured data
• ☑ Map data to standardized coding systems
• ☑ Conduct quality assurance and validation
• ☑ Maintain data security and audit trails
• ☑ Report findings using real-world contexts

Conclusion: A Roadmap to Reliable RWE via EHRs

EHRs offer a powerful and scalable solution to generate high-quality real-world evidence. From feasibility studies to long-term safety tracking, they unlock new research possibilities that go beyond traditional clinical trials. However, navigating EHR data complexity, privacy laws, and ethical boundaries is critical for successful implementation.

By following this structured approach and aligning with industry expectations on pharmaceutical stability testing, pharma professionals can confidently integrate EHRs into their RWE strategy and enhance the impact of their research on real-world patient outcomes.